Annual Drug Patent Expirations for ZEPOSIA Zeposia is a drug marketed by Bristol and is included in one NDA. It is available from one supplier. There are five patents protecting…
Source
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are ten…
Source
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPatentWatch.com
Source
Annual Drug Patent Expirations for FYCOMPA Fycompa is a drug marketed by Catalyst Pharms and is included in two NDAs. It is available from two suppliers. There are two patents…
Source
Rifaximin is the generic ingredient in one branded drug marketed by Salix Pharms and is included in one NDA. There are twenty-nine patents protecting this compound. Drug patent litigation for…
Source
New tentative approval for Sandoz Inc drug rifaximin Read Post »
This chart shows the drugs with the most patents in Argentina. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…
Source
Which pharmaceutical drugs have the most drug patents in Argentina? Read Post »
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPatentWatch.com
Source
Rifaximin is the generic ingredient in one branded drug marketed by Salix Pharms and is included in one NDA. There are twenty-nine patents protecting this compound. Drug patent litigation for…
Source
New tentative approval for Sandoz Inc drug rifaximin Read Post »
Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs. This is one of the longest exclusivity terms provided by…
Source
Pharmaceutical companies with the most ‘New Chemical Entity’ drugs Read Post »
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPatentWatch.com
Source
Get new actionable insights and updates from BiotechBlog
